Randomized Controlled Trial of Intravenous Ferric Carboxymaltose for Iron-Deficiency Anemia in Patients With Advanced Gastric Cancer Receiving Palliative Chemotherapy

Not Applicable

• Conditions: Neoplasms

• Registration Number: KCT0006908
• Lead Sponsor: Asan Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2022

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 330

Inclusion Criteria

1. Age = 19 years at the time of study registration
2. Eastern Cooperative Oncology Group performance status = 2
3. Histologically or cytologically confirmed gastric or gastroesophageal junction (GEJ) adenocarcinoma
4. Locally advanced unresectable or metastatic disease
5. Patients who have not been treated with palliative systemic antitumor agents for advanced or recurrent gastric or GEJ adenocarcinoma
6. Patients scheduled to receive palliative first-line fluoropyrimidine and platinum-based systemic therapy including targeted therapy or immunotherapy
7. Life expectancy =24 weeks
8. IDA
a. Hb 8 to <11 g/dL
b. Absolute ID (serum ferritin < 100 ng/mL)
OR functional ID (TSAT* < 50% and serum ferritin 100-500 ng/mL)
*TSAT = (serum iron level x 100)/ total iron-binding capacity (TIBC)

Exclusion Criteria

Inclusion Criteria
1. Age = 19 years at the time of study registration
2. Eastern Cooperative Oncology Group performance status = 2
3. Histologically or cytologically confirmed gastric or gastroesophageal junction (GEJ) adenocarcinoma
4. Locally advanced unresectable or metastatic disease
5. Patients who have not been treated with palliative systemic antitumor agents for advanced or recurrent gastric or GEJ adenocarcinoma
6. Patients scheduled to receive palliative first-line fluoropyrimidine and platinum-based systemic therapy including targeted therapy or immunotherapy
7. Life expectancy =24 weeks
8. IDA
a. Hb 8 to <11 g/dL
b. Absolute ID (serum ferritin < 100 ng/mL)
OR functional ID (TSAT* < 50% and serum ferritin 100-500 ng/mL)
*TSAT = (serum iron level x 100)/ total iron-binding capacity (TIBC)

Exclusion Criteria
1. Body weight < 35 kg
2. Immediate need for transfusion or Hb < 8 g/dL
3. Possible functional ID or No ID (serum ferritin > 500 ng/mL OR TSAT = 50%)
4. Anemia attributable to factors other than cancer or chemotherapy (e.g., vitamin B12 and/or serum folate deficiency; hemolysis; or myelodysplastic syndromes)
5. Ongoing bleeding or overt gross active bleeding (e.g., hematemesis, melena, or hematochezia)
6. Neoplastic bone marrow infiltration
7. History of ESA, IV or oral iron therapy, and/or RBC transfusion 4 weeks prior to randomization
8. Iron overload or disturbances in utilization of iron (e.g., personal or family history of hemochromatosis and hemosiderosis)
9. Known hypersensitivity to any of the required study products or known serious hypersensitivity to other parenteral iron products
10. Known severe allergies including drug allergies, history of severe asthma, eczema or other atopic allergies, and in subjects with immune or inflammatory conditions (e.g., systemic lupus erythematosus, rheumatoid arthritis)
11. Decreased renal function including renal dialysis (previous, current or planned within the next 6 months,) or serum creatinine levels = 2.0 mg/dL, or estimated glomerular filtration rate < 30 mL/min/1.73 m2
12. Chronic liver disease (including active hepatitis) and/or aspartate transaminase (AST) or alanine transaminase (ALT) = 3 times the upper limit of the normal range
13. Active acute or chronic infections (assessed by clinical judgment)
14. Other significant medical condition(s) in the opinion of the investigator with an anticipated need for major surgery during the study, or any other kind of disorder that may be associated with increased risk to the subject or may interfere with study assessments, outcomes (e.g., uncontrolled hypertension, active cardiac disease, thromboembolic disease, or uncontrolled diabetes mellitus, neurological or psychiatric disorders)
15. Pregnancy (e.g., positive human chorionic gonadotropin test) or breast-feeding. If the subject is of childbearing potential and does, not use adequate contraceptive precautions. The subject must agree to use adequate contraception during the study and for 1 month after the last dose of study treatment. A highly effective method of birth control must be used.

Study & Design

• Study Type: Interventional Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Maximum change of Hb concentration from baseline to 12 weeks (or first RBC transfusion and/or ESA, or study withdrawl, or death, whichever will be first) without RBC transfusion and/or ESA

Secondary Outcome Measures

Name	Time	Method
Change of Hb concentration from baseline to 3, 6, 9, 12, 24, 36, and 48 weeks;Change in serum iron, ferritin, TIBC, and TSAT from baseline to 3, 6, 9, 12, 24, 36, and 48 weeks;Tumor response as assessed by investigators according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1);progression-free survival [PFS];overall survival [OS];Change in QOL score from baseline to 6, 12, 24, 36 and 48 weeks ;safety